Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Program: Scientific Session
General Topic: Clinical

Breathing New Life into Pulmonary Sarcoidosis: Updates and Ongoing Challenges in Evaluation and Treatment of Disease

Sunday, October 26, 2025
3:00 PM – 4:00 PM Central Time

    Moderator(s)

  • GB

    Genna Braverman, MD, MSc (she/her/hers)

    Hospital for Special Surgery
    New York, New York, United States

    Disclosure(s): No financial relationships with ineligible companies to disclose

  • JA

    James Andrews, MD

    University of Alabama at Birmingham
    Birmingham, Alabama, United States

    Disclosure(s): No financial relationships with ineligible companies to disclose

  • Kristen Mathias, MD, MHS (she/her/hers)

    Johns Hopkins Hospital
    Baltimore, Maryland, United States

    Disclosure(s): No financial relationships with ineligible companies to disclose

    • Session Coordinator(s)

  • AG

    Angelo Gaffo, MD, FACP

    University of Alabama at Birmingham
    Birmingham, AL, United States

    Disclosure(s): AVALO: Consultant (Ongoing)

  • DF

    David Fernandez, MD, PhD

    Hospital for Special Surgery
    New York, New York, United States

    Disclosure information not submitted.

Sarcoidosis is a multiorgan disease of granulomatous inflammation that is associated with significant morbidity and mortality, and most commonly involves the lungs. Pulmonary sarcoidosis is clinically heterogenous with many mimics and unreliable biomarkers. This session aims to provide healthcare professionals with an in-depth understanding of the evaluation and treatment of pulmonary sarcoidosis. Participants will explore the varied clinical presentations of pulmonary sarcoidosis, including phenotypes of pulmonary function test abnormalities seen in patients and chest imaging patterns in affected patients. The session will cover essential diagnostic tools, including imaging studies (chest X-ray, CT, and PET/CT), pulmonary function tests (PFTs), and biopsy techniques. It will also emphasize how to differentiate pulmonary sarcoidosis from other connective tissue-related interstitial lung diseases using these parameters. Established and emerging immunosuppressive treatment approaches will be reviewed along with their evidence basis. Finally, the session will highlight the management of advanced pulmonary sarcoidosis, including therapeutic considerations for pulmonary fibrosis and pulmonary hypertension.

Learning Objectives:

  • Identify the clinical manifestations of pulmonary sarcoidosis, including common and atypical symptoms, and understand how these presentations can vary across patient populations
  • Utilize diagnostic tools effectively for evaluating pulmonary sarcoidosis, including advanced chest imaging, pulmonary function tests, and bronchoscopy
  • Differentiate pulmonary sarcoidosis from other connective tissue-related interstitial lung diseases (ILDs) using clinical, radiological, and functional parameters
  • Critically assess the evidence supporting various immunosuppressive treatment strategies for pulmonary sarcoidosis and develop a personalized treatment approach based on disease severity and patient characteristics
  • Recognize the management of advanced pulmonary sarcoidosis, including therapeutic options for complications such as pulmonary fibrosis and pulmonary hypertension

Presentations:

  • 3:00 PM – 3:30 PM Central Time
    Navigating the Complexities of Pulmonary Sarcoidosis: From Diagnosis to Evaluation of Disease Phenotypes

    Speaker: Michelle Sharp, MD, MHS – Johns Hopkins

  • 3:30 PM – 4:00 PM Central Time
    What Is New in the Treatment of Sarcoidosis?

    Speaker: Robert Baughman, MD, PhD – University of Cincinnati